Comparative Evaluation of Glomerular and Tubular Function Abnormalities in Patients with Different Forms of β-Thalassemia, an Emerging Concern
Journal of Pediatric Nephrology,
Vol. 7 No. 2 (2019),
31 Shahrivar 2019
,
Page 1-7
https://doi.org/10.22037/jpn.v7i2.27833
Abstract
Thalassemia syndromes are the most prevalent hereditary hemoglobinopathy in the world. Reduction or absence of β-chain synthesis is the hallmark of β-thalassemia syndromes, resulting in an excess of alpha chains. In all of the patients with thalassemia major (TM) and some patients with thalassemia intermedia (TI), repeated and regular transfusions are the main part of treatment. In β-thalassemia minor, the patients are asymptomatic and diagnosis is often based upon hematologic parameters on CBC and hemoglobin electrophoresis. Both tubular and glomerular dysfunctions have been reported in three forms of β-thalassemia, but these changes are more prominent in TM and TI. Iron overload due to repeated transfusions, chronic anemia, and the toxicity of iron chelator drugs such as deferoxamine and deferasirox are the main factors in the pathogenesis of nephropathy in patients with transfusion-dependent thalassemia (TDT). In this review, the mechanism of renal disease in thalassemia, comparative assessment of kidney dysfunction in three variant forms of β-thalassemia, and markers of tubular and glomerular dysfunction have been discussed.
Keywords: Thalassemia; Anemia; Kidney; child.How to Cite
References
Sankaran VG, Nathan DG, and Orkin SH. Thalassemia. In: Orkin SH, Fisher DE, Ginsburg D, Look AT, Lux SE, Nathan DG, eds. Nathan and Oski’s Hematology of Infancy and Childhood, 8th ed. Philadelphia: Saunders; 2015:715–768.
Borgna-Pignatti C, Marsella M, Zanforlin N. The natural history of thalassemia intermedia. Ann N Y Acad Sci 2010;1202:214–20.
Chapin J and Giardina PJ. Thalassemia syndromes. In: Hoffman R, Benz EJ, , Silberstein LE, Heslop HE, Weitz JI, Anastasi J, Salama M, eds. Hematology: basic principles and practice, 7th edition. Philadelphia: Elsevier, 2018:546-7.
Saliba AN, Harb AR, Taher AT. Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med. 2015;6:197-209.
Said F, Abdel-Salam A. Xmn I polymorphism: Relation to β-thalassemia phenotype and genotype in Egyptian Children. Egypt J Med Hum Genet 2015:16(2):123-7.
Ansari SH, Shamsi TS, Munzir S, et al. Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion.J Pediatr Hematol Oncol. 2013 May;35(4):e153-6.
Miri M, Tabrizi Namini M, Hadipour Dehshal M, Sadeghian Varnosfaderani F, Ahmadvand A, Yousefi Darestani S, Manshadi M. Thalassemia in Iran in last twenty years: the carrier rates and the births trend. Iran J Blood Cancer. 2013 Nov 15;6(1):11-7.
Hashemieh M, Timori Naghadeh H, Tabrizi Namini M, Neamatzadeh H, Hadipour Dehshal M. The Iran Thalassemia Prevention Program: Success or Failure? Iran J Ped Hematol Oncol 2015;5(3):161-6.
Şen V, Ece A, Uluca Ü, Söker M, Güneş A, Kaplan İ, Tan İ, Yel S, Mete N, Sahin C. Urinary early kidney injury molecules in children with beta-thalassemia major. Renal failure. 2015 Apr 21;37(4):607-13.
Sleiman J, Tarhini A, Taher AT. Renal complications in thalassemia. Thalassemia Reports. 2018;8:7481:41-9
Ahmadzadeh A, Jalali A, Assar S, Khalilian H, Zandian K, Pedram M. Renal tubular dysfunction in pediatric patients with beta-thalassemia major. Saudi Journal of Kidney Diseases and Transplantation. 2011 May 1;22(3):497.
Koliakos G, Papachristou F, Koussi A, Perifanis V, Tsatra I, Souliou E, Athanasiou M. Urine biochemical markers of early renal dysfunction are associated with iron overload in β‐thalassaemia. Clinical & Laboratory Haematology. 2003 Apr;25(2):105-9.
Ali BA and Sultan AM. Frequency of Glomerular Dysfunction in Children with Beta Thalassae¬mia Major. Sultan Qaboos Univ Med J .2014;14:e88-94
Hashemieh M, Azarkeivan A, Akhlaghpoor S, Shirkavand A, Sheibani K.T2-star (T2*) magnetic resonance imaging for assessment of kidney iron overload in thalassemic patients. Arch Iran Med.2012;15(2):91-4.
Shirkavand A, Mokhtari Hesari P, Akhlaghpoor Sh, Azarkeivan A, Hashemieh M. Renal Iron Load Estimation in Thalassemia Patients Using T2* Magnetic Resonance Imaging. International Journal of Medical Research & Health Sciences, 2019, 8(4):182-9
Bakr A, Al-Tonbary Y, Osman G, El-Ashry R. Renal complications of beta-thalassemia major in children. Am J Blood Res. 2014;4(1):1-6.
Nangaku M. Chronic hypoxia and tubulointerstitial Injury: A final common pathway to end-stage renal failure. J Am Soc Nephrol .2006;17:17-25.
Mallat NS, Mallat SG, Musallam KM, Taher AT. Potential mechanisms for renal damage in beta-thalassemia. Journal of Nephrology. 2013;26(5):821-8.
Ponticelli C, Musallam KM, Cianciulli P, Cappellini MD. Renal complications in transfusion-dependent beta thalassaemia. Blood Rev. 2010 Nov;24(6):239-44.
Lai ME, Spiga A, Vacquer S, Carta MP, Corrias C, Ponticelli C. Renal function in patients with β-thalassaemia major: a long-term follow-up study. Nephrol Dial Transplant.2012;27:3547-3551.
Hamed EA, El Melegy NT. Renal functions in pediatric patients with thalassemia major: relation to chelation therapy: original prospective study. Ital J Pediatr. 2010;36(1):39.
Shlipak MG, Matsushita K, Ärnlöv J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369(10):932-43.
Sadeghi-Bojd S, Hashemi M, Karimi M. Renal tubular function in patients with beta-thalas¬semia major in Zahedan, southeast Iran. Sin¬gapore Med J .2008;49:410-2.
Mohkam M, Shamsian BS, Gharib A, Nariman S,Arzanian MT. Early markers of renal dys-function in patients with beta-thalassemia. Pediatr Nephrol 2008;23:971-6.
Hashemieh M, Radfar M, Azarkeivan A, et al. Renal Hemosiderosis among Iranian Transfusion Dependent β-Thalassemia Major Patients. Int J Hematol Oncol Stem Cell Res. 2017;11(2):133-8.
Tantawy AA, El Bablawy N, Adly AA, Ebeid FS. Early predictors of renal dysfunction in Egyptian patients with β-thalassemia major and intermedia. Mediterranean journal of hematology and infectious diseases. 2014;6(1).
Quinn CT, Johnson VL, Kim HY, Trachtenberg F, Vogiatzi MG, Kwiatkowski JL, Neufeld EJ, Fung E, Oliveri N, Kirby M, Giardina PJ. Renal dysfunction in patients with thalassaemia. British journal of haematology. 2011 Apr;153(1):111-7.
Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta haematologica. 2010;123(3):148-52.
Xu Y, Xie Y, Shao X, Ni Z, Mou S .L-FABP: A novel biomarker of kidney disease. Clin Chim Acta. 2015;445:85-90.
Uwaezuoke SN, Ayuk AC, Muoneke VU, Mbanefo NR. Chronic kidney disease in children: Using novel biomarkers as predictors of disease. Saudi Journal of Kidney Diseases and Transplantation. 2018 Jul 1;29(4):775.
Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221–6.
Behairy OG, Almonaem ER, Abed NT, Haiea OM, Zakaria RM, AbdEllaty RI, Asr EH, Mansour AI, Abdelrahman AM, Elhady HA. Role of serum cystatin-C and beta-2 microglobulin as early markers of renal dysfunction in children with beta thalassemia major. International journal of nephrology and renovascular disease. 2017;10:261.
Papassotiriou I, Margeli A, Hantzi E, Delaporta P, Sergounioti A, Goussetis E. Cystatin C levels in patients with beta-thalassemia during deferasirox treatment. Blood Cells Mol Dis. 2010;44(3):152-5.
Voskaridou E, Terpos E, Michail S, Hantzi E, Anagnostopoulos A, Margeli A, et al. Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia. Kidney Int. 2006;69(11):2037-42.
Bekhit OEL, El Dash HH, Ahmed MS. Early detection of kidney dysfunction in Egyptian patients with beta-thalassemia major. Egyptian Pediatric Association Gazette 2017 Sep 1;65(3):85-9.
Kacar AG, Silfeler I, Kacar A, Pekun F, Turkkan E, Adal E. Levels of beta-2 microglobulin and cystatin C in beta thalassemia major patients.J Clin Anal Med. 2015;6(3):269–73.
Sumboonnanonda A, Malasit P, Tanphaichitr VS, Ong-ajyooth S, Petrarat S, Vongjirad A. Renal tubular dysfunction in alpha-thalassemia. Pediatr Nephrol. 2003;18(3):257-60.
Roudkenar MH, Halabian R, Oodi A, Roushandeh AM, Yaghmai P, Najar MR, et al. Upregulation of neutrophil gelatinase-associated lipocalin, NGAL/Lcn2, in beta-thalassemia patients. Arch Med Res. 2008;39(4):402-7.
Uzun E, Balcı YI, Yüksel S, Aral YZ, Aybek H, Akdağ B. Glomerular and tubular functions in children with different forms of beta thalassemia. Ren Fail. 2015;37(9):1414-8.
40-Adly AA, Toaima DN, Mohamed NR, Seoud KM. Subclinical renal abnormalities in young thalassemia major and intermedia patients and its relation to chelation therapy. The Egyptian Journal of Medical Human Genetics 2014;15: 369–77.
Taher AT, Musallam KM, Cappellini MD,Weatherall DJ: Optimal management of beta thalassaemia intermedia. Br J Haematol 2011;152:512–23.
Ziyadeh FN, Musallam KM, Mallat NS, Mallat S, Jaber F, Mohamed AA, Koussa S, Taher AT. Glomerular hyperfiltration and proteinuria in transfusion-independent patients with β-thalassemia intermedia. Nephron Clin Pract. 2012;121(3-4):c136-43.
Smolkin V, Halevy R, Levin C, Mines M, Sakran W, Ilia K, Koren A. Renal function in children with β-thalassemia major and thalassemia intermedia. Pediatric nephrology. 2008 Oct 1;23(10):1847.
Ali D, Mehran K, Moghaddam AG: Comparative evaluation of renal findings in beta thalassemia major and intermedia. Saudi J Kidney Dis Transpl 2008;19:206–9.
Nickavar A, Qmarsi A, Ansari S, Zarei E. Kidney Function in Patients with Different Variants of Beta-Thalassemia. Iran J Kidney Dis. 2017 Mar;11(2):132-7.
Prabahar MR, Jain M, Chandrasekaran V, Indhumathi E, Soundararajan P. Renal tubular dysfunction with nephrocalcinosis in a patient with beta thalassemia minor. Saudi J Kidney Dis Transpl. 2008 Nov;19(6):964-8.
Cetin T, Oktenli C, Ozgurtas T, Yenicesu M, Sanisoglu SY, Oguz Y, Yildiz O, Kurt I, Musabak U, Bulucu F, Kocar IH. Renal tubular dysfunction in β-thalassemia minor. American journal of kidney diseases. 2003 Dec 1;42(6):1164-8.
Kalman S, Atay AA, Sakallioglu O, Özgürtaş T, Gök F, Kurt İ, Kürekçi AE, Özcan O, Gökçay E. Renal tubular function in children with beta-thalassemia minor. Nephrology (Carlton). 2005 Oct;10(5):427-9.
Sadeghi-Bojd S, Hashemi M, Naderi M, Shikhani S. Kidney function tests in children with beta-thalassemia minor in Zahedan, southeast of Iran. Iran J Kidney Dis. 2011 Jul;5(3):201-3.
Greep N, Anderson AL, Gallagher JC. Thalassemia minor: A risk factor for osteoporosis. Bone Miner. 1992;16:63–72.
Kalef-Ezra J, Challa A, Chaliasos N et al. Bone minerals in beta thalassemia minor. Bone 1995;16:651–5.
Alon US, Berenbom A. Idiopathic hypercalciuria of childhood: 4- to 11-year outcome. Pediatr. Nephrol. 2000;14:1011–5.
- Abstract Viewed: 354 times
- PDF Downloaded: 208 times